MCID: FML037
MIFTS: 53

Female Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 12 15
Female Breast Carcinoma 12 15 73
Malignant Neoplasm of Female Breast 73
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 50 C2918

Summaries for Female Breast Cancer

Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to adenoid cystic carcinoma and breast cancer. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are DNA Double-Strand Break Repair and Pathways in cancer. The drugs Epirubicin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 adenoid cystic carcinoma 29.6 ATM ERBB2 PGR TP53
2 breast cancer 29.5 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
3 in situ carcinoma 29.4 BRCA1 ERBB2 ESR1 PGR TP53
4 endometrial cancer 29.4 AR BRCA1 BRCA2 ERBB2 ESR1 PGR
5 breast carcinoma in situ 29.3 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
6 female breast nipple and areola cancer 11.1
7 female breast central part cancer 11.1
8 female breast lower-outer quadrant cancer 11.1
9 female breast upper-inner quadrant cancer 11.1
10 female breast lower-inner quadrant cancer 11.1
11 female breast axillary tail cancer 11.1
12 female breast upper-outer quadrant cancer 11.1
13 endometrium carcinoma in situ 10.3 PGR TP53
14 scirrhous adenocarcinoma 10.3 ERBB2 PGR
15 breast apocrine carcinoma 10.3 ERBB2 PGR
16 vestibular gland benign neoplasm 10.3 ESR1 PGR
17 bartholin's gland adenoma 10.3 ESR1 PGR
18 vulvar syringoma 10.3 ESR1 PGR
19 intracystic papillary adenoma 10.3 ERBB2 PGR
20 lung leiomyoma 10.3 ESR1 PGR
21 vulvar benign neoplasm 10.3 ESR1 PGR
22 breast malignant phyllodes tumor 10.3 PGR TP53
23 trigonitis 10.3 ESR1 PGR
24 vulvar leiomyoma 10.3 ESR1 PGR
25 breast metaplastic carcinoma 10.3 ERBB2 PGR
26 progesterone-receptor negative breast cancer 10.2 ERBB2 PGR
27 gastric papillary adenocarcinoma 10.2 ERBB2 TP53
28 predominantly cortical thymoma 10.2 ESR1 PGR
29 olfactory groove meningioma 10.2 PGR TP53
30 bartholin's gland benign neoplasm 10.2 ESR1 PGR
31 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
32 tracheoesophageal fistula with or without esophageal atresia 10.2 BRCA2 PALB2
33 progesterone resistance 10.2 ESR1 PGR
34 isolated tracheoesophageal fistula 10.2 BRCA2 PALB2
35 cribriform carcinoma 10.2 ESR1 PGR
36 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
37 comedo carcinoma 10.2 ERBB2 ESR1
38 endometrial mucinous adenocarcinoma 10.2 ESR1 PGR
39 adenoid basal cell carcinoma 10.2 ESR1 PGR
40 deep angioma 10.2 ESR1 PGR
41 pancreatic neuroendocrine tumor 10.2 BRCA2 PALB2
42 breast squamous cell carcinoma 10.2 ERBB2 TP53
43 bartholin's duct cyst 10.2 AR TP53
44 estrogen excess 10.2 ESR1 PGR
45 anterior cranial fossa meningioma 10.2 PGR TP53
46 intramuscular hemangioma 10.2 ESR1 PGR
47 hereditary site-specific ovarian cancer syndrome 10.2 BRCA1 BRCA2
48 glioma susceptibility 1 10.2 ERBB2 TP53
49 uterine body mixed cancer 10.2 ERBB2 PGR TP53
50 cervical clear cell adenocarcinoma 10.2 ESR1 PGR

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.17 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.17 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.17 BRCA1 BRCA2 PALB2 PGR
4 Decreased homologous recombination repair frequency GR00236-A-2 10.17 ATM BRCA1 BRCA2 PALB2 PGR
5 Decreased homologous recombination repair frequency GR00236-A-3 10.17 BRCA1 BRCA2 PALB2
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
8 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.5 ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A
9 Decreased viability after ionizing radiation GR00232-A-2 9.33 ATM BRCA1 BRCA2
10 Decreased TP53 mRNA expression GR00389-S-5 9.26 ATM TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 AR ATM BRCA1 BRCA2 ERBB2 ERCC4
2 growth/size/body region MP:0005378 10.22 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
3 behavior/neurological MP:0005386 10.21 AR ATM BRCA1 BRCA2 ERBB2 ESR1
4 cardiovascular system MP:0005385 10.2 AR ATM BRCA1 CYP1A1 ERBB2 ESR1
5 homeostasis/metabolism MP:0005376 10.2 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
6 endocrine/exocrine gland MP:0005379 10.19 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
7 mortality/aging MP:0010768 10.18 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2
8 embryo MP:0005380 10.16 AR ATM BRCA1 BRCA2 ERBB2 ESR1
9 integument MP:0010771 10.13 AR ATM BRCA1 BRCA2 ERBB2 ESR1
10 limbs/digits/tail MP:0005371 10.01 AR BRCA1 BRCA2 ERBB2 ESR1 PALB2
11 digestive/alimentary MP:0005381 10 AR BRCA1 BRCA2 ERBB2 ESR1 TP53
12 neoplasm MP:0002006 9.91 AR ATM BRCA1 BRCA2 ERBB2 ESR1
13 muscle MP:0005369 9.8 AR BRCA1 ERBB2 ESR1 PGR TP53
14 normal MP:0002873 9.76 AR BRCA1 BRCA2 CYP1A1 ERBB2 ESR1
15 reproductive system MP:0005389 9.61 AR ATM BRCA1 BRCA2 ERBB2 ESR1
16 skeleton MP:0005390 9.17 AR BRCA1 BRCA2 ERBB2 ESR1 PGR

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 222)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 4,Phase 3,Phase 1,Phase 2 56420-45-2 41867
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Fluorouracil Approved Phase 4,Phase 3 51-21-8 3385
4
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
5
Methylene blue Approved, Investigational Phase 4 61-73-4
6
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
7
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 437-38-7 3345
9
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 114977-28-5 148124
10
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2 112809-51-5 3902
11
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
12
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
13
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
16
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 31703
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anesthetics, Inhalation Phase 4,Not Applicable
21 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
22 Platelet Aggregation Inhibitors Phase 4,Not Applicable
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
24 Anesthetics, Intravenous Phase 4,Phase 2,Not Applicable
25 Anesthetics, General Phase 4,Phase 2,Not Applicable
26 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Narcotics Phase 4,Phase 2,Not Applicable
29 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
30 Adjuvants, Anesthesia Phase 4,Phase 2,Not Applicable
31 Analgesics, Opioid Phase 4,Phase 2,Not Applicable
32 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Calcium, Dietary Phase 4,Phase 2,Not Applicable,Early Phase 1
34 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2
37 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
38 Estrogen Antagonists Phase 4,Phase 3,Phase 2
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
43 Aromatase Inhibitors Phase 4,Phase 3,Phase 2
44 Anesthetics, Local Phase 4,Phase 3,Phase 2,Not Applicable
45 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
46 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 taxane Phase 4,Not Applicable
48 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 183)
# Name Status NCT ID Phase Drugs
1 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
2 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Unknown status NCT02982148 Phase 4
3 Anesthesia and Circulating Tumor Cells in Breast Cancer Completed NCT02005770 Phase 4 Sevoflurane;Propofol
4 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4 Toremifene; Anastrozole
5 PEMF and PEC Blocks in Mastectomy Reconstruction Patients Recruiting NCT03360214 Phase 4 Bupivacaine Hydrochloride
6 Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy Recruiting NCT03051503 Phase 4 The Transdermal Therapeutic System-Fentanyl (TTS-F)
7 Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia Recruiting NCT03812003 Phase 4 Remifentanil
8 Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide Active, not recruiting NCT02502864 Phase 4 Standard of Care: Docetaxel;Standard of Care: Cyclophosphamide
9 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
10 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
11 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Unknown status NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
12 Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. Completed NCT03381417 Phase 3 pegcyte;Neulastim
13 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
14 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer Completed NCT03403712 Phase 3 fosnetupitant/ palonosetron;netupitant/palonosetron;dexamethasone
15 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
16 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
17 Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life Recruiting NCT03585218 Phase 3
18 Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Recruiting NCT03351062 Phase 3 Tamoxifen;Toremifene
19 Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients Recruiting NCT03525990 Phase 3
20 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate Recruiting NCT02600923 Phase 3 Palbociclib;Letrozole
21 Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block Not yet recruiting NCT03063073 Phase 3 Dexmedetomidine Injection [Precedex];Bupivacaine
22 Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Not yet recruiting NCT03686215 Phase 3
23 Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients Unknown status NCT01168505 Phase 2 ferric hydroxide saccharate
24 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction Completed NCT01466270 Phase 2 donepezil hydrochloride;Placebo
25 Treatment for Patients Suffering From Anemia Due to Chemotherapy Completed NCT00120692 Phase 2 Darbepoetin Alfa;Recombinant Human Erythropoietin
26 Dose Dense TC + Pegfilgrastim Support for Breast Cancer Completed NCT01671319 Phase 2 docetaxel + cyclophosphamide + pegfilgrastim
27 Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Completed NCT01204125 Phase 2 paclitaxel;Iniparib (SAR2405550 -BSI-201)
28 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
29 Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT02527746 Phase 1, Phase 2 EC regimen
30 The HEALS Project - Health Education and Active Living for Surviving Seniors Completed NCT01305044 Phase 2
31 Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor Recruiting NCT03518138 Phase 2 Q-122;Placebo
32 Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications Recruiting NCT03518242 Phase 2 Cyclophosphamide;Methotrexate;Capecitabine
33 Immunogenicity and Safety of DCs in Breast Cancer Recruiting NCT03450044 Phase 1, Phase 2
34 Tissue Stresses of Cancer (Force Horizon 2020) Recruiting NCT03238144 Phase 1, Phase 2
35 Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) Recruiting NCT03065621 Phase 2 Palbociclib
36 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Recruiting NCT02942355 Phase 2 anastrozole;Palbociclib
37 Study on Androgen Receptor and Triple Negative Breast Cancer Recruiting NCT03383679 Phase 2 Darolutamide;Capecitabine
38 Combination Study of SV-BR-1-GM in Combination With Pembrolizumab Recruiting NCT03328026 Phase 1, Phase 2 Low dose cyclophosphamide
39 Effect of Methylphenidate on Cancer-related Cognitive Impairment Recruiting NCT02970500 Phase 2 Methylphenidate HCl 10Mg SR;Placebo Group
40 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Recruiting NCT02540330 Phase 2 Fulvestrant
41 Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting NCT03342417 Phase 2
42 PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Recruiting NCT03084536 Phase 2 Bupivacaine;Gabapentin;Celecoxib;Acetaminophen;Midazolam;Fentanyl
43 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Recruiting NCT03112590 Phase 1, Phase 2 Paclitaxel;Trastuzumab
44 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Recruiting NCT03113825 Phase 2 AVB-620
45 Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Recruiting NCT03384914 Phase 2
46 Denosumab as an add-on Neoadjuvant Treatment (GeparX) Recruiting NCT02682693 Phase 2 Denosumab;nab-Paclitaxel;Epirubicin;Cyclophosphamide;Carboplatin;Trastuzumab;Pertuzumab
47 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Recruiting NCT03250676 Phase 1, Phase 2 H3B-6545
48 Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 Recruiting NCT03630809 Phase 2
49 Phase II Trial for Large ER-Negative Breast Cancers Active, not recruiting NCT01869192 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
50 Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer Active, not recruiting NCT01203839 Phase 2

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

41
Breast, Lymph Node, Bone, Prostate, Lung, Heart, Cortex

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 447)
# Title Authors Year
1
Acceptability and satisfaction of Project MOVE: a pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors. ( 29409128 )
2018
2
Natural Terpenoids Against Female Breast Cancer: a 5-year Recent Research. ( 29446727 )
2018
3
Survival Comparisons Between Early Male and Female Breast Cancer Patients. ( 29891971 )
2018
4
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. ( 29098396 )
2018
5
Improving Visualization of Female Breast Cancer Survival Estimates: Analysis Using Interactive Mapping Reports. ( 29724710 )
2018
6
Ambient air emissions of polycyclic aromatic hydrocarbons and female breast cancer incidence in US. ( 29730800 )
2018
7
Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting. ( 29280294 )
2018
8
Personality risk factors of occurrence of female breast cancer: a case-control study in China. ( 29699414 )
2018
9
Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. ( 29678178 )
2018
10
Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29294225 )
2018
11
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. ( 29396493 )
2018
12
Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. ( 29804200 )
2018
13
Health-related quality of life of African-American female breast cancer survivors, survivors of other cancers, and those without cancer. ( 29704078 )
2018
14
Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10-year (2006-2015) retrospective hospitalization summary report-based study. ( 29624915 )
2018
15
Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. ( 29673111 )
2018
16
Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis. ( 29478945 )
2018
17
A Comparison Between Upper Arm and Chest for Optimal Site of Totally Implanted Venous Access Ports in Patients with Female Breast Cancer. ( 29481918 )
2018
18
Work and Female Breast Cancer: The State of the Evidence, 2002-2017. ( 29658425 )
2018
19
Breast specific functional and symptom analysis in female breast cancer survivors. ( 29893309 )
2018
20
Influence of social conditions on the quality of life of female breast cancer survivors. ( 30557918 )
2018
21
Is there an association between liraglutide use and female breast cancer in a real-world setting? ( 30538516 )
2018
22
Trends in incidence and mortality of female breast cancer during transition in Central China. ( 30538571 )
2018
23
PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. ( 30519815 )
2018
24
Expression of chemerin correlates with a poor prognosis in female breast cancer patients. ( 30498371 )
2018
25
Second primary cancer after female breast cancer: Familial risks and cause of death. ( 30479046 )
2018
26
Dosage-dependent reduction of macular pigment optical density in female breast cancer patients receiving tamoxifen adjuvant therapy. ( 29660599 )
2018
27
Hypermethylated LATS2 gene with decreased expression in female breast cancer: A case control study from North India. ( 30010037 )
2018
28
Factors Associated with Functional Decline in Elderly Female Breast Cancer Patients in Appalachia. ( 30027004 )
2018
29
Prevention of Acute Radiation-Induced Skin Reaction with NPE® Camellia Sinensis Nonfermentatum Extract in Female Breast Cancer Patients Undergoing Postoperative Radiotherapy: A Single Centre, Prospective, Open-Label Pilot Study. ( 30057821 )
2018
30
Evaluation of the delivery of survivorship care plans for South Asian female breast cancer survivors residing in Canada. ( 30111971 )
2018
31
Occupational variation in the risk of female breast cancer in the Nordic countries. ( 30151565 )
2018
32
Male breast cancer: a disease distinct from female breast cancer. ( 30267249 )
2018
33
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. ( 30297439 )
2018
34
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. ( 30371238 )
2018
35
Prognostic Influence of Preoperative Mammographic Breast Density in Operable Invasive Female Breast Cancer. ( 30375450 )
2018
36
DDT exposure in early childhood and female breast cancer: Evidence from an ecological study in Taiwan. ( 30376997 )
2018
37
Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project. ( 28223083 )
2017
38
Estimated and Interactively Visualized Female Breast Cancer Incidence Rates in Missouri Senate Districts: 2008-2012. ( 29403576 )
2017
39
BRIP1/FANCJ Mutation Analysis in a Family with History of Male and Female Breast Cancer in India. ( 28382101 )
2017
40
No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations. ( 28490891 )
2017
41
Metastasis and its Related Factors in Female Breast Cancer Patients in Kerman, Iran ( 28669169 )
2017
42
[The coping styles and its relationship with quality of life among 1 968 female breast cancer patients in Shanghai in 2014]. ( 28763916 )
2017
43
Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients. ( 29135103 )
2017
44
Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study. ( 28732040 )
2017
45
Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. ( 28607590 )
2017
46
Province Disparity on Female Breast Cancer in Iran. ( 29259957 )
2017
47
Physical symptoms and working performance in female breast cancer survivors: a systematic review. ( 28325132 )
2017
48
Marital adjustment in the context of female breast cancer: A systematic review. ( 28342270 )
2017
49
Model-based Recursive Partitioning for Survival of Iranian Female Breast Cancer Patients: Comparing with Parametric Survival Models. ( 28451527 )
2017
50
Exploring neighborhood inequality in female breast cancer incidence in Tehran using Bayesian spatial models and a spatial scan statistic. ( 28774168 )
2017

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.07 ATM BRCA1 BRCA2 ERCC4 PALB2 TP53
2 12.7 AR BRCA2 ERBB2 ESR1 TP53
3
Show member pathways
12.58 ATM BRCA1 BRCA2 ERBB2 ESR1 TP53
4
Show member pathways
12.55 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
5
Show member pathways
12.45 ATM BRCA1 BRCA2 ERCC4 ESR1 TP53
6 12.39 ATM BRCA1 ERBB2 TP53
7
Show member pathways
12.02 ATM BRCA1 BRCA2 PALB2
8
Show member pathways
12.02 ATM BRCA1 BRCA2 ERCC4 PALB2
9 11.97 ATM BRCA1 BRCA2 ERCC4 PHB TOP2A
10 11.86 ATM ERBB2 TP53
11
Show member pathways
11.83 ERBB2 ESR1 PGR
12 11.77 BRCA1 BRCA2 ERCC4 PALB2
13
Show member pathways
11.74 AR ESR1 PGR
14
Show member pathways
11.71 ATM BRCA1 TP53
15
Show member pathways
11.68 ATM BRCA1 BRCA2 TP53
16 11.48 ATM BRCA1 BRCA2 TP53
17 11.42 ATM BRCA1 ERBB2 TOP2A TP53
18
Show member pathways
11.41 AR BRCA1 ESR1
19 11.4 ATM BRCA1 TP53
20 11.38 ATM BRCA1 ERBB2 TP53
21 11.37 ATM BRCA1 TP53
22 11.35 AR ATM BRCA1 BRCA2 ESR1 PHB
23 11.21 ATM BRCA1 TP53
24 11.15 ATM BRCA1 TP53
25
Show member pathways
10.98 ATM TP53
26 10.93 ATM BRCA1 TP53
27 10.73 CYP1A1 ESR1

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.77 AR ATM BRCA1 BRCA2 ERBB2 ERCC4
2 protein-containing complex GO:0032991 9.63 AR BRCA1 BRCA2 ESR1 TOP2A TP53
3 nuclear chromosome, telomeric region GO:0000784 9.5 ATM BRCA2 ERCC4
4 nucleoplasm GO:0005654 9.36 AR ATM BRCA1 BRCA2 ERCC4 ESR1
5 lateral element GO:0000800 9.26 BRCA1 BRCA2
6 cytoplasm GO:0005737 10.11 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 AR ATM BRCA1 ESR1 PGR TOP2A
2 cell proliferation GO:0008283 9.88 AR BRCA2 CYP1A1 ERBB2 TP53
3 protein deubiquitination GO:0016579 9.87 AR BRCA1 ESR1 TP53
4 DNA repair GO:0006281 9.83 ATM BRCA1 BRCA2 ERCC4 PALB2
5 positive regulation of gene expression GO:0010628 9.8 AR ATM BRCA1 ERBB2 PHB TP53
6 DNA recombination GO:0006310 9.79 BRCA1 BRCA2 PALB2
7 multicellular organism growth GO:0035264 9.75 AR BRCA2 PALB2
8 double-strand break repair via nonhomologous end joining GO:0006303 9.72 ATM BRCA1 ERCC4
9 steroid hormone mediated signaling pathway GO:0043401 9.71 AR ESR1 PGR
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.7 ATM BRCA1 BRCA2
11 positive regulation of transcription, DNA-templated GO:0045893 9.7 AR BRCA1 BRCA2 ESR1 PHB TOX3
12 nucleotide-excision repair GO:0006289 9.67 BRCA2 ERCC4 TP53
13 double-strand break repair via homologous recombination GO:0000724 9.67 BRCA1 BRCA2 ERCC4 PALB2
14 response to immobilization stress GO:0035902 9.64 CYP1A1 PHB
15 resolution of meiotic recombination intermediates GO:0000712 9.63 ERCC4 TOP2A
16 mammary gland alveolus development GO:0060749 9.63 AR ESR1
17 DNA double-strand break processing GO:0000729 9.62 ATM BRCA1
18 replicative senescence GO:0090399 9.61 ATM TP53
19 inner cell mass cell proliferation GO:0001833 9.61 BRCA2 PALB2
20 negative regulation of telomerase activity GO:0051974 9.6 ERCC4 TP53
21 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.59 ESR1 TP53
22 positive regulation of transcription by RNA polymerase III GO:0045945 9.58 AR ERBB2
23 progesterone receptor signaling pathway GO:0050847 9.56 PGR PHB
24 chordate embryonic development GO:0043009 9.51 BRCA1 BRCA2
25 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.46 AR PGR
26 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 BRCA1 BRCA2 TP53
27 regulation of apoptotic process GO:0042981 9.43 ATM BRCA1 ESR1 PHB TOX3 TP53
28 cellular response to DNA damage stimulus GO:0006974 9.17 ATM BRCA1 BRCA2 ERCC4 PALB2 TOP2A

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.96 AR BRCA1 ESR1 PGR TP53
2 identical protein binding GO:0042802 9.87 BRCA1 BRCA2 ERBB2 ERCC4 ESR1 PGR
3 chromatin binding GO:0003682 9.83 AR ESR1 TOP2A TOX3 TP53
4 transcription regulatory region DNA binding GO:0044212 9.8 AR BRCA1 PHB TP53
5 histone deacetylase binding GO:0042826 9.72 PHB TOP2A TP53
6 protein N-terminus binding GO:0047485 9.71 ATM ERCC4 TP53
7 DNA binding GO:0003677 9.7 AR ATM BRCA1 BRCA2 ERCC4 ESR1
8 ATPase binding GO:0051117 9.69 AR ESR1 PGR
9 steroid hormone receptor activity GO:0003707 9.65 AR ESR1 PGR
10 nuclear receptor activity GO:0004879 9.58 AR ESR1 PGR
11 protein C-terminus binding GO:0008022 9.55 BRCA2 ERBB2 ERCC4 PHB TOP2A
12 TFIID-class transcription factor complex binding GO:0001094 9.52 ERCC4 TP53
13 estrogen response element binding GO:0034056 9.46 ESR1 TOX3
14 steroid binding GO:0005496 9.43 AR ESR1 PGR
15 enzyme binding GO:0019899 9.23 AR BRCA1 CYP1A1 ESR1 PGR PHB
16 protein binding GO:0005515 10.21 AR ATM BRCA1 BRCA2 CYP1A1 ERBB2

Sources for Female Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....